April 20, 2021 -- Code Biotherapeutics has launched with $10 million in financing and will focus on next-generation nonviral gene therapies.
The Philadelphia-based company has developed a proprietary synthetic DNA-based vector called 3DNA that has the potential to deliver genes of all sizes to multiple cell types as a redosable therapy for the treatment of many genetic disorders. Code is developing a pipeline of novel gene therapies to treat rare genetic diseases such as Duchenne muscular dystrophy and type 1 diabetes. The company is also actively seeking partnerships in other strategic areas.
The seed financing was co-led by 4BIO Capital and UPMC Enterprises, with participation from CureDuchenne Ventures, JDRF T1D Fund, New Enterprise Associates, and Takeda Ventures.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
